Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23506498 | 0.96 | CTSL (0.47) | CTSLNPC1RAB9ACTSBALDH1A1 | |
| SCHEMBL23711798 | 0.92 | CTSL (0.46) | CTSLNPC1RAB9ACTSBALDH1A1 | |
| SCHEMBL23506443 | 0.92 | CTSL (0.46) | CTSLNPC1RAB9ACTSBALDH1A1 | |
| SCHEMBL26494427 | 0.90 | NPC1 (0.48) | CTSLNPC1RAB9ACTSBALDH1A1 | |
| SCHEMBL21702097 | 0.90 | NPC1 (0.48) | CTSLNPC1RAB9ACTSBALDH1A1 | |
| SCHEMBL21702170 | 0.85 | CTSL (0.44) | CTSLCTSBALDH1A1 | |
| SCHEMBL23506299 | 0.85 | CTSL (0.44) | CTSLCTSBALDH1A1 | |
| SCHEMBL26495046 | 0.85 | CTSL (0.47) | CTSLRAB9ACTSB | |
| SCHEMBL23506340 | 0.84 | CTSL (0.48) | CTSLRAB9AALDH1A1 | |
| SCHEMBL23711883 | 0.84 | CTSL (0.48) | CTSLRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151387-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | CTSL 1/4885NPC1 499/4885RAB9A 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.